Join us at the Influenza Vaccines for the World Conference in Lausanne, Switzerland, April 19-21, 2017. Dr. Kathy Rowlen will be speaking about the VaxArray platform and I&L Biosystems will be representing InDevR with a table top booth. Please contact us if you wish to schedule a time to meet.
InDevR Appoints Dawn Bitz as Chief Commercial Officer
Addition Strengthens Executive Team and Provides Demonstrated Leadership in Executing Commercial Strategies for Life Sciences Products
BOULDER, CO (June 28, 2016) — InDevR, a Boulder-based progressive analytical technology, life science instrumentation and medical device company, announced the appointment of Dawn Bitz as Vice President, Chief Commercial Officer, effective immediately. Prior to joining InDevR, Mrs. Bitz, was a successful entrepreneur and executive holding $500M+ global P&L responsibilities.
“Dawn is a tremendous leader who will build a world-class commercial team at InDevR,” said Dr. Kathy Rowlen, Chief Executive Officer. “Her experience in growing world-class businesses, planning and executing commercial strategies and overseeing multiple launches will play a critical role in InDevR’s next phase of growth”.
During her outstanding 20+ year career, Mrs. Bitz has been a successful corporate executive, entrepreneur and consultant. She has held prominent positions with multi-billion dollar medical device and pharmaceutical companies, consulted for small and mid-cap companies, led mergers and integrations of $250M acquisitions, and has held $500M+ P&L responsibilities globally. Early in Ms. Bitz’ career she worked clinically on the ambulance and in the hospital and managing both pharmaceutical and medical device research studies. She translated that foundation into a successful business management and commercial career. Ms. Bitz has led global marketing, sales, product development, business development and commercial operations for companies like Covidien, Boston Scientific and UCB Pharma. She also founded and sold a consumer product goods and technology company. Ms. Bitz will lead InDevR’s commercial efforts, including product sales, marketing, business development and licensing, communications, public relations and investor relations.
Ms. Bitz holds undergraduate degrees in biology and chemistry from Texas Christian University and is a registered nurse and paramedic.
“I am excited to join InDevR at a time when we have the opportunity to shape commercial strategies for new and innovative ways to streamline and expedite the commercial vaccine production process. I look forward to building and leading a top-tier organization that will impact our ability to fight influenza and other public health issues,” said Mrs. Bitz.
InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. For more information about the company and products, please visit www.indevr.com or call 303-402-9100.
InDevR Announces Creation of Strategic Advisory Board
Esteemed Group of Leaders in Influenza Preparedness and Biotechnology Business to Help Company Maximize Product Potential
Boulder, CO – SEPTEMBER 30, 2015 – InDevR, Inc., an innovative biotechnology company dedicated to improving diagnostics and vaccine manufacturing, today announced the formation of the InDevR Strategic Advisory Board, an esteemed group of scientific and business leaders chosen to counsel the company on the opportunities for maximizing the impact of its technologies globally.
Kathy Rowlen, Ph.D., Chief Executive Officer of InDevR commented, “With a series of new game-changing technologies now on the market and our FluChip-8G™ system in design and development, the time is right to begin thinking more broadly about the range of business development opportunities available to us.” The new advisors include:
- Nancy Cox, Ph.D. Dr. Cox is the retired Director of the Influenza Division at the Centers for Disease Control and Prevention, and the former Director of its WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza. During her CDC tenure, Dr. Cox helped transform the surveillance and science of influenza viruses and vaccines worldwide. She was the recipient of the Service to America Medals Federal Employee of the Year Award in 2006 and the CDC’s Lifetime Achievement Award in 2014. Time magazine named her one of 2006’s 100 Most Influential People of the Year and Newsweek magazine honored her as one of the “15 People Who Make America Great.”
- Caren Mason. Ms. Mason is the CEO of STAAR Surgical and former CEO of Verinata Health, Quidel Corporation, MiraMedica and eMed Technologies. She has served on several corporate and philanthropic boards, including STAAR, HealthTell, and the Executive Committee of the University of California San Diego Moores Cancer Center Board of Visitors.
- Klaus Stöhr, Ph.D. Dr. Stöhr was until recently Vice President and Head of Global Policy for Novartis Vaccines. Prior to Novartis he worked at WHO, as coordinator of the WHO Global Influenza Program and also as Special Advisor on Influenza Pandemic Vaccine Development for the WHO Initiative for Vaccine Research. He was included in the 2005 Scientific American 50 list of research and policy leaders.
“After decades of working on the science of influenza prevention and control, I am excited to be associated with InDevR, a company with demonstrated commitment to improved influenza diagnosis and development of new tools for more efficient manufacturing of vaccines,” said Dr. Cox. “Their product portfolio has great potential to improve prevention and control of influenza viruses as well as a host of other infectious diseases.”
“InDevR is now at a stage where its products can make a significant contribution to expedited access to seasonal influenza vaccine and more rapid disease diagnosis in people,” said Dr. Stöhr. “InDevR’s new analytical tools for vaccine manufacturing have the potential for faster release and use of pandemic influenza vaccine from many producers in case of a global health emergency.”
“We are excited about the future of InDevR and are delighted that these leaders share in our enthusiasm and recognize the potential for our technologies on a global scale,” continued Dr. Rowlen. “Nancy and Klaus bring an incomparable wealth of knowledge about influenza diagnostics, vaccines, virology, and global trends, and Caren brings tremendous business insight and savvy to aid our mission. I am deeply grateful that these remarkable individuals have joined our efforts.”
The FluChip-8G product in development at InDevR is a multiplexed influenza diagnostic that will enable physicians to identify seasonal influenza viruses and distinguish them from novel potentially pandemic influenza viruses. The development effort is supported by BARDA contract HHSO100201400010C. Over the past two years, the company introduced two new products for vaccine manufacturing: the Cypher One™ system to standardize the hemagglutination inhibition assays that are used to characterize new strains of influenza, and the VaxArray™ Influenza potency assay, a multiplexed immunoassay for hemagglutinin protein quantification. Development of both products was supported by the Small Business Innovation Research (SBIR) program at the National Institutes of Allergy and Infectious Disease (R43 AI106054, R44AI102318, respectively).
Neither HHS, NIAID, CDC nor BARDA are responsible for the contents of this release. The statements contained in this release do not constitute endorsement or recommendation by the U.S. Government.
InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing diagnostics, vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. For more information about the company and products, please visit www.indevr.com or call 303-402-9100.